57 completed, 17 terminated, 9 unknown, 5 withdrawn. 50 Phase 2, 27 Phase 1, 20 Phase 3, 3 Not applicable, 1 Phase 4.
Follow LV: new trials by email Literature Review of LV trials Research Report on LV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma Irinotecan Hydrochloride Liposome Injection, 5-FU, LV - Neuroendocrine Carcinomas (NEC) | Phase 4 | Not yet recruiting | Beijing GoBroad Hospital | 45 | 2025-06-20 | 2025-06-11 |
| Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC liposomal irinotecan, 5-FU, LV - Esophageal Cancer | Phase 3 | Not yet recruiting | Rui-hua Xu, MD, PhD | 360 | 2024-08-01 | 2024-07-15 |
| Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer Irinotecan Liposome, 5-FU, LV - Metastatic Colorectal Cancer | Phase 2 | Recruiting | West China Hospital | 86 | 2024-06-30 | 2024-08-12 |
| Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV Irinotecan liposoma, oxaliplatin, bevacizumab - Advanced Pancreatic Cancer (Part 1) | Phase 1 / Phase 2 | Recruiting | Dai, Guanghai | 138 | 2024-06-23 | 2025-01-20 |
| Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer Adebrelimab, Oxaliplatin 100 MG, Irinotecan liposome - Pancreatic Cancer | Phase 2 | Unknown | Fudan University | 87 | 2024-06-05 | 2024-08-09 |
| HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer HR070803, Oxaliplatin, Tegafur - Efficacy and Safety | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 120 | 2024-04-20 | 2024-04-25 |
| Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer Irinotecan Liposome, Oxaliplatin, 5-FU - Metastatic Colorectal Cancer | Phase 1 | Unknown | Shanghai Zhongshan Hospital | 78 | 2024-03-11 | 2024-03-19 |
| A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer Fluorouracil, Leucovorin, Oxaliplatin - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Terminated | Baylor College of Medicine | 3 | 2024-03-06 | 2026-04-09 |
| Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX Irinotecan liposome injection, Oxaliplatin, 5-FU - Pancreatic Cancer | Phase 2 | Not yet recruiting | Changhai Hospital | 134 | 2024-02-01 | 2024-01-18 |
| Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer liposomal irinotecan, 5-FU, LV - Colorectal Cancer | Phase 2 | Recruiting | Hebei Medical University Fourth Hospital | 173 | 2024-01-01 | 2024-10-09 |
| AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 AZD0901, 5-Fluorouracil, Leucovorin - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 2 | Recruiting | AstraZeneca | 226 | 2023-12-13 | 2026-09-30 |
| A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer Fosifloxuridine Nafalbenamide, Leucovorin, Irinotecan - Colorectal Cancer, Colorectal Neoplasms | Phase 2 | Terminated | NuCana plc | 180 | 2023-04-18 | 2025-09-12 |
| NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer Irinotecan Liposomal Injection [Onivyde], Capecitabine, 5-fluorouracil - Pancreatic Cancer | Phase 2 | Unknown | Seoul National University Hospital | 200 | 2020-06-23 | 2024-04-19 |
| CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC Bevacizumab, 5-fluorouracil, Leucovorin calcium - Metastatic Colorectal Cancer | Phase 2 | Unknown | Chugai Pharmaceutical | 112 | 2019-10-11 | 2019-10-31 |
| Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers Oxaliplatin, Albumin-Bound Paclitaxel /nab-Paclitaxel, S-1 - Gastric Cancer in Situ, Pancreatic Cancers | Phase 1 | Completed | National Health Research Institutes, Taiwan | 18 | 2018-06-26 | 2022-04-07 |
| Post Marketing Surveillance Study for ONIVYDE® in South Korea ONIVYDE, 5-fluorouracil, Leucovorin - Metastatic Pancreatic Cancer | Completed | Institut de Recherches Internationales Servier | 94 | 2018-03-08 | 2021-09-28 | |
| Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer ladiratuzumab vedotin, Pembrolizumab - Triple Negative Breast Neoplasms | Phase 1 / Phase 2 | Completed | Seagen Inc. | 185 | 2018-02-27 | 2025-12-12 |
| FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients Irinotecan, 5-fluorouracil, Leucovorin - Colorectal Carcinoma | Phase 3 | Unknown | Fudan University | 164 | 2016-10-01 | 2016-10-17 |
| Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma carfilzomib, cyclophosphamide, vincristine sulfate - Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma | Phase 1 | Completed | Mehrdad Abedi, MD | 10 | 2015-12-17 | 2022-03-10 |
| Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma nal-IRI, 5 fluorouracil, Leucovorin - Pancreatic Cancer | Phase 2 | Completed | Ipsen | 56 | 2015-10-19 | 2022-10-10 |
Showing 20 of 96. Sign in to see all of them.
Colonic Neoplasms (25) · Rectal Neoplasms (25) · Colorectal Neoplasms (19) · Pancreatic Neoplasms (14) · Stomach Neoplasms (11) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Esophageal Neoplasms (5) · Adenocarcinoma Of Esophagus (4) · Neoplasm Metastasis (3) · Bile Duct Neoplasms (2) · Biliary Tract Neoplasms (2) · Esophageal Squamous Cell Carcinoma (2) · Gallbladder Neoplasms (2) · Osteosarcoma (2) · Triple Negative Breast Neoplasms (2)
National Cancer Institute (NCI) (26) · City of Hope Medical Center (6) · Fudan University (4) · Children's Oncology Group (3) · ECOG-ACRIN Cancer Research Group (3) · University of Southern California (3) · Case Comprehensive Cancer Center (2) · Fox Chase Cancer Center (2) · Hellenic Oncology Research Group (2) · John Hays (2) · Roswell Park Cancer Institute (2) · Seagen Inc. (2) · University Hospital of Crete (2) · AstraZeneca (1) · BTG International Inc. (1)
United States (70) · China (11) · Canada (8) · Australia (7) · Spain (6) · Germany (4) · Greece (4) · Puerto Rico (4) · South Korea (4) · United Kingdom (4) · Italy (3) · Japan (3) · Poland (3) · Chile (2) · France (2)
Marwan Fakih (3) · Afsaneh Barzi (2) · Al Benson (2) · Crystal Denlinger (2) · Heinz-Josef Lenz (2) · John Hays, MD (2) · John Souglakos, MD (2) · Ruihua Xu, Professor (2) · Zejing Wang, MD, PhD (2) · Akihito Tsuji, M.D., Ph.D. (1) · Al B. Benson, MD, FACP (1) · Allyson Ocean (1) · Andrea Wang-Gillam, M.D., PhD (1) · Anthony LA Fields, MD, FRCPC (1) · Aref Al-Kali, M.D. (1)
PMID 31268130, PMID 33356421, PMID 16877719, PMID 17470851, PMID 17853393, PMID 20233444, PMID 21208843, PMID 21859995, PMID 21997132, PMID 22240792, PMID 22474202, PMID 23293700, PMID 23623224, PMID 24077846, PMID 24220557, PMID 27055731, PMID 27270348, PMID 27871319, PMID 27913881, PMID 28006055, PMID 28419486, PMID 28495639, PMID 28983557, PMID 30117142, PMID 30525443, PMID 30679026, PMID 30825970, PMID 30957229, PMID 31378656, PMID 31811950, PMID 32001530, PMID 32085892, PMID 32154021, PMID 32165096, PMID 32649004, PMID 32703200, PMID 33203692, PMID 33242441, PMID 33863713, PMID 33957442, PMID 34019214, PMID 34162404, PMID 34750990, PMID 35069808, PMID 35963480, PMID 36306483, PMID 36606664, PMID 37678921, PMID 38315963, PMID 38900452
U10CA098543 (7), U10CA021115 (5), U10CA032102 (3), 2015 (2), N01CM00070 (2), P30CA014089 (2), U01CA069856 (2), U10CA023318 (2), U10CA025224 (2), 2017 (1), N01CM00038 (1), N01CM00071 (1), N01CM62201 (1), N01CM62204 (1), P01CA043904 (1)